Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
about
Intensive glucose control versus conventional glucose control for type 1 diabetes mellitusIntensive glucose control versus conventional glucose control for type 1 diabetes mellitusEffects of intensive glucose lowering in type 2 diabetesThe effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study.The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD studyEpidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial.Long-term effects of intensive glucose lowering on cardiovascular outcomes.Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial.Severe hypoglycemia symptoms, antecedent behaviors, immediate consequences and association with glycemia medication usage: Secondary analysis of the ACCORD clinical trial dataNear-Normalization of Glucose and Microvascular Diabetes Complications: Data from ACCORD and ADVANCE.Sirtuins as novel players in the pathogenesis of diabetes mellitus.Effect of intensive glycemic lowering on health-related quality of life in type 2 diabetes: ACCORD trial.Impact of intensive glycemic control on the incidence of atrial fibrillation and associated cardiovascular outcomes in patients with type 2 diabetes mellitus (from the Action to Control Cardiovascular Risk in Diabetes Study)Diabetes performance measures: current status and future directions.Body mass index-mortality relationship in severe hypoglycemic patients with type 2 diabetesA Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V).The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trialConstructing common cohorts from trials with overlapping eligibility criteria: implications for comparing effect sizes between trials.Poor cognitive function and risk of severe hypoglycemia in type 2 diabetes: post hoc epidemiologic analysis of the ACCORD trialEffects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy.Hypoglycemia, diabetes, and cardiovascular disease.Admission hyperglycemia and acute myocardial infarction: outcomes and potential therapies for diabetics and nondiabetics.Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type 2 diabetic patients.What do we need beyond hemoglobin A1c to get the complete picture of glycemia in people with diabetes?Durable change in glycaemic control following intensive management of type 2 diabetes in the ACCORD clinical trialShould We Use PPAR Agonists to Reduce Cardiovascular Risk?Stress Perfusion Cardiac Magnetic Resonance Imaging Effectively Risk Stratifies Diabetic Patients With Suspected Myocardial Ischemia.Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studiesInsulin Dose and Cardiovascular Mortality in the ACCORD Trial.Effect of interactions between C peptide levels and insulin treatment on clinical outcomes among patients with type 2 diabetes mellitus.Incorporating Concomitant Medications into Genome-Wide Analyses for the Study of Complex Disease and Drug ResponseEffects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial.Evaluation of an automated method to assist with error detection in the ACCORD central laboratory.Control of postprandial glucose levels with insulin in type 2 diabetes.Vascular imaging in diabetes.Glucose targets for preventing diabetic kidney disease and its progression.Glycemic Control and Excess Cardiovascular Mortality in Type 1 Diabetes.Risk of Cardiovascular Events in Patients With Diabetes Mellitus on β-Blockers.Glucose: archetypal biomarker in diabetes diagnosis, clinical management and research.Factors associated with failure to achieve a glycated haemoglobin target of <8.0% in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
P2860
Q24200376-281BE073-BA14-4EDA-9C35-9B9B9CCAA01CQ24234960-55E3986F-245F-4A43-BC55-0A2CC7698A46Q29547736-4A71D1BD-6BE4-49B9-B660-78115AF2429FQ33579759-2A13B5EB-6FD2-417C-A7E3-499313756C61Q33579765-B2E9AA39-79FC-440E-9DDA-D14F8D7BFD15Q33804791-1B6A281C-6A3A-4620-BDC3-86298AFA4174Q33851861-D92E7E11-ABF6-41C8-BE5D-14067E171BE8Q34008233-B4B99615-8CED-495E-B3B6-1F29ABCF6246Q34286013-B718A44E-D589-4BF9-8917-231B912BF451Q34475442-B1E26503-6784-48D1-A1A5-4D8328B29E6EQ34699239-B59E2346-5FA9-4746-9A97-94AD8B939FE9Q34718335-17FA9E36-D96F-49FB-86CB-7ED91B27A972Q34921180-FBA923EE-DD2E-47EE-89E3-AF2D7B842A67Q35060223-7BD8B084-B24E-460A-A7A4-CABCE36F173CQ35141312-874E00C7-D8D2-409A-8048-8B3311EE7796Q35329472-A17287D2-3141-4465-BBEA-604D1C14D77BQ35630701-7A0E9BA3-8B93-430C-AEC7-E7655FCB4649Q35661637-D6FE22AC-D731-44B0-B915-EE18CBD33677Q35841183-36056981-87C8-4FD1-ADFD-3421D642668BQ35905639-1351E00C-85BD-408D-9D3E-B40C27080F2DQ35990856-F50669D5-CDBC-438F-96AB-787CF3D196FCQ36102103-B49A7F40-97CA-4692-A5AB-539FE8007C43Q36270259-3F4E8F86-284D-427F-B510-3642BCF22FA9Q36302225-F4761FB2-D500-4A8F-88E1-CA1701606B7FQ36424107-127C04C3-83B3-4883-A734-31C7D2DAEAF9Q36446970-1AAFF336-DA60-422B-9BBF-12F1A9EC443FQ36787048-20B578F2-B282-4AFB-9049-F75BECE33B00Q36807402-064341C1-633D-41D9-9700-84E40D508E1EQ36926409-42D98B77-9BBD-4A91-A59D-BBE73D0FC621Q37163138-E52E693A-2048-400C-B4C3-B590B5911F33Q37236166-988C3B2D-1F8A-4942-BBBC-4A0609C98C65Q37597008-DE435092-8EA6-405F-BA24-166FA8F0D1A4Q37767086-0B6575B9-2AA8-4020-818B-40C9AB19D0A2Q37890790-794420FB-175F-45B3-BB83-271A903453ACQ38184961-8CF07570-BDC6-4B7A-B931-799224CC6FC7Q38736800-B6FAD7AF-04C3-4413-B0A9-AFC6B86B747AQ38737217-07F02473-3ABD-44B8-840A-8342FADC0281Q38755607-DC65B32C-A963-4BD2-BBEC-838FB1B9875DQ39296810-F130C375-6182-4F3D-A866-73B53E5387B9Q40468686-3A1C1BBD-EA2A-44C6-8AA8-B84FFD86E553
P2860
Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Glycemia treatment strategies ...... sk in Diabetes (ACCORD) trial.
@en
type
label
Glycemia treatment strategies ...... sk in Diabetes (ACCORD) trial.
@en
prefLabel
Glycemia treatment strategies ...... sk in Diabetes (ACCORD) trial.
@en
P2093
P1476
Glycemia treatment strategies ...... sk in Diabetes (ACCORD) trial.
@en
P2093
ACCORD Study Group
Bruce P Hamilton
David M Kendall
Faramarz Ismail-Beigi
Julienne K Kirk
Mark N Feinglos
Matthew C Riddle
Patricia Feeney
Robert M Cohen
P304
P356
10.1016/J.AMJCARD.2007.03.004
P407
P577
2007-04-19T00:00:00Z